FDA Authorizes Digital Therapeutic for Sleep Disturbance in PTSD
NightWare is a smartwatch application that uses the Apple Watch and Apple iPhone platform.
Post-Traumatic Stress Disorder
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Neither Psychotherapy Nor Medications Favored for PTSD
Evidence insufficient to determine whether psychotherapy, medications are more effective
Stellate Ganglion Block Treatment Evaluated for PTSD
among patients who received stellate ganglion block (n=74), the adjusted mean CAP-5 total symptom severity score change from baseline was -12.6 points (95% CI, -15.5, -9.7 points) vs -6.1 points (95% CI, -9.8, -2.3 points) for those who received sham treatment
FDA Clears Freespira Digital Therapeutic for Post-Traumatic Stress Disorder
Palo Alto Health Sciences announced that the FDA has granted clearance to Freespira, a new digital therapeutic for the treatment of PTSD.
Phase 3 Trial of Potential PTSD Treatment Halted
Participants in the trial were randomized to receive Tonmya 5.6mg sublingually at bedtime for 12 weeks or placebo sublingual tablets.
Various PTSD Treatments Evaluated in Updated Review
To update a previous review, researchers searched various databases from May 2012 to September 2017 to identify studies comparing the safety and efficacy of various PTSD interventions.
MDMA-Assisted Psychotherapy Reduces PTSD Symptoms
MDMA-assisted psychotherapy effective, well tolerated for veterans and first responders with PTSD
Prazosin Ineffective for Alleviating PTSD-Related Nightmares, Says Study
For veterans with chronic PTSD, no significant difference in distressing dreams, sleep quality
FDA Greenlights MDMA Studies for Posttraumatic Stress Disorder
“Our Phase 2 data was extremely promising with a large effect size, and we are ready to move forward quickly,” said Amy Emerson, Executive Director of the MAPS Public Benefit Corporation.
